Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01457677 · ClinicalTrials.gov registry record · Phase 2
ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 357
- Enrollment target
NCT01457677 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 357 participants.
The verdict
NCT01457677, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 357 participants
- Enrollment target
Study Summary
This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4995819 as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment. Patients will be randomized to receive once daily doses of 5 mg, 15 or 30 mg of RO4995819 or matching placebo. The anticipated time on study treatment is 6 weeks.
Interventions
- DRUG Placebo
- DRUG RO4995819
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 357 participants |
| Start Date | 2011-12 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01457677
The ClinicalTrials.gov registry entry for NCT01457677 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 357 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01457677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01457677 about?
NCT01457677 is a clinical study titled "ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment". This multi-center, randomized, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of RO4995819 as adjunctive therapy in patients with major depressive disorder having inadequate response to ongoing antidepressant treatment. Patients will be randomized to ...
What is the current status of trial NCT01457677?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 357 participants. The study started on 2011-12. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01457677?
The interventions under investigation include: Placebo (DRUG), RO4995819 (DRUG).
Who is sponsoring clinical trial NCT01457677?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.